Publications

Peer-reviewed original research articles:

  1. Korach KS, Chae K, Gibson M and Curtis S. Estrogen Receptor Stereochemistry: Ligand Binding and Hormonal Responsiveness. Steroids 56: 263-270, 1991.
  2. Gibson M, Nemmers L, Beckman W, Davis V, Curtis S and Korach KS. The Mechanism of ICI 164,384 Antiestrogenicity Involves Rapid Loss of Estrogen Receptor in Uterine Tissue. Endocrinology 129: 2000-2010, 1991.
  3. Chae K, Gibson M and Korach KS. Estrogen Receptor Stereochemistry: Ligand Binding Orientation and Influence on Biological Activity. Molecular Pharmacology 40: 806-811, 1991.
  4. Migliaccio S, Davis V, Gibson M, Gray TK and Korach KS. Estrogens Modulate the Responsiveness of Osteoblast-Like Cells (ROS 17/2.8) Stably Transfected with Estrogen Receptor. Endocrinology 130: 2617-2624, 1992.
  5. Gibson M and Moore T. Tropical Pyomyositis in a Man from St. Croix. J. Travel Medicine 2: 101-102, 1995.
  6. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Stürzbecher H.-W., Hoeijmakers JHJ and Harris, CC. Abrogation of p53 Induced Apoptosis by the Hepatitis B Virus X Gene. Cancer Research 55: 6012-6016, 1995.
  7. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L,
  8. Yeh H, Hoeijmakers JHJ and Harris CC. The XPB and XPD DNA Helicases are Components of the p53-mediated Apoptosis Pathway. Genes and Development 10:1219- 1232, 1996.
  9. Buchhop S, Gibson MK, Wang XW, Wagner P, Stürzbecher H.-W. and Harris CC. Interaction of p53 With the Human RAD51 Protein. Nucleic Acids Research 25 (19): 3868- 3874, 1997.
  10. Gibson MK, Villano SA and Huff CA. Recrudescence of Cutaneous Mycobacterium haemophilum Lesions Following Tetanus Immunization. Clinical Infectious Diseases 28: 919-920, 1999.
  11. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E and Forastiere AA. Epidermal Growth Factor Receptor, p53 Mutation and Pathologic Response Predict Survival in Patients with Locally Advanced Esophageal Cancer Treated with Pre-operative Chemoradiotherapy. Clinical Cancer Research 9(17): 6461-6468, 2003.
  12. Gibson MK, Holcroft CA, Kvols LK and Haller DH. Phase II Study of 5-Fluorouracil, Doxorubicin and Mitomycin C for Metastatic Small Bowel Adenocarcinoma. The Oncologist 10:132-137, 2005.
  13. Gibson MK, Li Y, Murphy B, Hussain, MHA, DeConti RC, Ensley J, Forastiere AA. Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 23(15):3562-3567, 2005.
  14. Ajani J, Bekaii-Saab T, D’Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 4(4):328-47, 2006.
  15. Ajani J, Bekaii-Saab T, D’Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M. Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 4(4):350-66, 2006.
  16. Montgomery E, Mamelak AJ, Gibson MK, Maitra A, Sheikh S, Amr SS, Yang S, Brock M, Forastiere A, Zhang S, Murphy KJ, Berg KD. Overexpression of Claudin Proteins in Esophageal Adenocarcinoma and Its Precursor Lesions. App Immunohistochem Mol Morphol 14(1):24-30, 2006.
  17. Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008 Jun;85(6):1930-6; discussion 1936-7
  18. Miyashita T, Shah FA, Marti G, Wang J, Armstrong T, Bonde P, Gibson MK, Yoshimura K, Montgomery EA, Duncan MD, Jaffee EM, Harmon JW. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting. J Gastrointest Surg 12:2-7; discussion 7-9, 2008.
  19. Miyashita T, Shah FA, Marti GP, Armstrong TD, Wang J, Bonde P, Gibson MK, Yoshimura K, Montgomery EA, Duncan M, Jaffee EM, Harmon JW. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting. Dig Dis Sci 53:2858-67, 2008.
  20. Daniels JA, Gibson MK, Xu L, Sun S, Canto, MI, Heath E, Wang J, Brock M, Montgomery E. Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. Am J Surg Pathol 32(3):473-7, 2008.
  21. Walvekar RR, Li RJ, Gooding WE, Gibson MK, Heron D, Johnson JT, Ferris RL. Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx. Laryngoscope 118:2129-34, 2008.
  22. Pennathur A, Farkas A, Krasinskas AM, Ferson PF, Gooding WE, Gibson MK, Schuchert MJ, Landreneau RJ, Luketich JD. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg 87:1048-54; discussion 1054-5, 2009.
  23. Feinstein TM, Gibson MK, Argiris A: Cetuximab-induced aseptic meningitis. Ann Oncol 20:1609-10, 2009
  24. Altiok S, Mezzadra H, Jagannath S, Tsottles N, Rudek MA, Abdallah N, Berman D, Forastiere A, Gibson MK. A Novel Pharmacodynamic Approach to Assess and Predict Tumor Response to the Epidermal Growth Factor Receptor Inhibitor Gefitinib in Patients with Esophageal Cancer. Int J Oncol 36(1):19-27, 2010.
  25. McLaughlin BT, Gokhale AS, Shuai Y, Diacopoulos J, Carrau R, Heron DE, Smith RP, Gibson MK, Ferris RL, Grandis JR, Johnson JT, Argiris A. Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. Laryngoscope 120:71-5, 2010.
  26. Rwigema JC, Heron DE, Ferris RL, Gibson M, Quinn A, Yang Y, Ozhasoglu C, Burton S. Fractionated Stereotactic Body Radiation Therapy in the Treatment of Previously-Irradiated Recurrent Head and Neck Carcinoma: Updated Report of the University of Pittsburgh Experience. Am J Clin Oncol. 2010 Jun;33(3):286-9324.
  27. Gokhale AS, McLaughlin BT, Flickinger JC, Beriwal S, Heron DE, Ferris RL, Johnson J, Gibson MK, Argiris A, Smith RP. Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers. Ann Oncol 21:145-51, 2010.
  28. Passero VA, Branstetter BF, Shuai Y, Heron DE, Gibson MK, Lai SY, Kim SW, Grandis JR, Ferris RL, Johnson JT, Argiris A. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol. 2010 Nov; 21(11):2278-83.
  29. Rwigema JC, Heron DE, Ferris RL, Andrade RS, Gibson MK, Yang Y, Ozhasoglu C, Argiris AE, Grandis JR, Burton SA. The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation Therapy. Am J Clin Oncol. 2011 Aug;34(4):372-9.
  30. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL. Concurrent Cetuximab With Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: A Single Institution Matched Case-Control Study. Am J Clin Oncol. 2011 Apr;34(2):165-72.
  31. Miyashita T, Shah FA, Marti GP, Wang J, Bonde P, Gibson MK, Ohta T, Montgomery EA, Duncan M, Harmon JW. Rabeprazole Impedes the Development of Reflux-Induced Esophageal Cancer in a Surgical Rat Model. Dig Dis Sci. 2011 May;56(5):1309-14.
  32. Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer. J Clin Oncol. 2010 Dec 20;28(36):5294-300.
  33. Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol. 2011 Nov;22(11):2482-8.
  34. Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70.
  35. Yoon HH, Catalano PJ, Murphy K, and Gibson MK: Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer 11:176, 2011.
  36. DeFoe SG, Pennathur A, Flickinger JC, Heron DE, Gibson MK, Luketich JD, Greenberger JS. Retrospective Review Of Patients With Locally-Advanced Esophageal Cancer Treated At The University Of Pittsburgh. Am J Clin Oncol. 2011 Dec; 34(6):587-92.
  37. Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T, Sasaki S, Oyama K, Miyashita T, Ohta T, Miwa K, Gibson MK, Zaidi A, Malhotra U, Atasoy A, Foxwell T, Jobe B: Barrett's esophagus and animal models. Ann N Y Acad Sci 1232:392-400, 2011.
  38. Nasu M, Gibson MK, Brock MA, Orita H, Xu L, Herman J, Forastiere AF, Kajiyama Y and Tsurumaru M. Field Defect of Methylation Changes in Esophageal Adenocarcinomas in Patients from Japan and the United States. Cancer Therapy Vol 8, 105-108, 2012.
  39. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck cancer. Ann Oncol. 2013 Jan;24(1):220-5.
  40. Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, Kosovec JE, Bhatt A, Malhotra U, Foxwell T, Rotoloni CL, Hoppo T, Jobe BA. Prevention of Barrett Esophagus and Esophageal Adenocarcinoma by Smoothened Inhibitor in a Rat Model of Gastroesophageal Reflux Disease. Ann Surg. 2012 Oct 26. [Epub ahead of print].
  41. Gomez-Casal R, Bhattacharya C, Ganesh N, Bailey L, Basse P, Gibson MK, Epperly M,and Levina V. Non-small Cell Lung Cancer Cells Survived Ionizing Radiation Treatment Display Cancer Stem Cell and Epithelial-Mesenchymal Transition Phenotypes. Molecular Cancer 2013, 12:94.
  42. Alejandro Nieponice, Adolfo E Badaloni, Blair A. Jobe, Toshitaka Hoppo, Carlos Pellegrini3, Vic Velanovich, Gary W Falk, Kevin Reavis, Lee Swanstrom, Virender K Sharma, Fabio Nachman, Franco F Ciotola, Luis E Caro, Cecilio Cerisoli, Demetrio Cavadas, Luis Durand Figueroa, Daniel Pirchi, Michael K. Gibson, Santiago Elizalde, Henry Cohen. Management of Early Stage Esophageal Neoplasia (MESEN) Consensus. World J. of Surgery. In Press.
  43. Gibson MK, Dhaliwal AS, Clemons NJ, Phillips WA, Dvorak K, Tong, D et al. Barrett’s Esophagus: Cancer and Molecular Biology. Ann NY Acad Sci. In Press.
  44. Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller R, Zeh HJ and Bahary N. Outcomes with FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer. J. Surgical Oncology. 2013, 108: 236-241.
  45. Usha Malhotra, dli H. Zaidi, Juliann E. Kosovec, Pashtoon M. Kasi, Yoshihiro Komatsu, Christina L. Rotoloni, Jon M. Davison, Clint R, Irvin, Toshitaka Hoppo, Katie S. Nason, MD Lori A. Kelly, Michael K. Gibson and Blair A. Jobe. Prognostic Value and Targeted Inhibition of Survivin Expression in Esophageal Adenocarcinoma and Cancer- Adjacent Squamous Epithelium. PLOS One. 2013 Nov 4;8(11):e78343.
  46. Nason K and Gibson MK et al. A Propensity-matched Analysis Comparing Survival After Primary Minimally Invasive Esophagectomy Followed by Adjuvant Therapy to Neoadjuvant Therapy for Esophagogastric Adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery. 2014, JTCVS-14-217R2. in press. 
Review Articles and Case Reports:
    1. Gibson MK and Forastiere AA. Multidisciplinary Approaches in the Management of Advanced Head and Neck Tumors: State of the Art. Current Opinion in Oncology 16(3): 220-224, 2004.
    2. Kleinberg L, Gibson MK, Yang S and Forastiere AA. The Minsky Article Reviewed. Oncology 20(5):505-511, 2004.
    3. Gibson MK and Forastiere AA. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncology 7(7):565-74, 2006.
    4. Gibson MK. Review: Targeting the Epidermal Growth Factor Receptor – Trials in Head and Neck and Lung Cancer. Oncology 20(2):172-5, 2006.
    5. Yoon H and Gibson MK. Combined Modality Therapy of Esophageal and Gastroesophageal Junction Cancer. Current Oncology Reports 9(3): 184-192, 2007.
    6. Kleinberg L, Gibson MK, and Forastiere AA. Chemoradiation for Esophageal Cancer, regima selection and molecular mechanism of radiosensitization. Nature Clinical Practice Oncology 4(5):282-94, 2007.
    7. Gibson MK. New Developments in the Treatment of Head and Neck Cancer: An Expert Interview With Dr. Michael K. Gibson. Medscape Hematology-Oncology 28 June 2007.
    8. Malhotra U and Gibson MK. Targeted Therapy: an Evolving Concept in Esophageal Adenocarcinoma. Oncology 24(12): 2010.
    9. Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL and Gibson MK. The Role of Cetuximab in the Management of Head and Neck Cancers. Expert Opinion in Biological Therapy, 12(4): 2012.
    10. Arjun Pennathur, Michael K Gibson, Blair A Jobe, James D Luketich. Oesophageal carcinoma. Lancet 2013; 381: 400–12.
    11. Yang Liu and Michael K Gibson. Esophageal Cancer—An Update Review. Oncology & Hematology Review, 2013;9(1):6–9.
    12. Bali GS, Hartman DJ, Haight JB, and Gibson MK. A Rare Case of Malignant Glomus Tumor of the Esophagus. Case Reports in Oncological Medicine. Volume 2013 (2013), Article ID 287078.
Editorials:
    1. Gibson MK and Forastiere AA. Combined-Modality Therapy for Esophageal Cancer: Are We Making Progress? The Cancer Journal 9(4): 238-240, 2003.
    2. Gibson MK and Forastiere AA. The Argiris/Jayaram/Pichardo Article Reviewed. Oncology 19(7): 939, 2005.
Book Chapters:
    1. Gibson MK and Forastiere AA. Cancer of the Esophagus. In: Bayless TM, Diehl A, editors. Advanced Therapy of Gastroenterology and Liver Disease 5/e. BD Decker, Inc. Hamilton, Ontario, p. 125-130, 2005.
    2. Gibson MK and Forastiere AA. Radiation Therapy, Chemoradiotherapy, and Neoadjuvant Approaches for Localized Esophageal Cancer. In: UpTo Date, continuously updated.
    3. Gibson MK and Heron DE. Management of Locally Advanced Unresectable Esophageal Cancer. In: UpToDate, continuously updated.
    4. Saltzman JR and Gibson, MK. Diagnosis and Staging of Esophageal Cancer. In: UpToDate, continuously updated.
    5. Gibson MK. Neoadjuvant and Primary Chemoradiation Strategies in the Treatment of Esophageal Cancer. In: Yuh D, editor. The Johns Hopkins Manual of Cardiothoracic Surgery, p. 295-307.
    6. Gibson MK. Neoadjuvant and Adjuvant Therapy of Esophageal Cancer in: Cameron, John L. Current Surgical Therapy, 9th edition, 10/2008.
    7. Karamouzis MV, Gibson MK, and Argiris, AA. The Contribution of Chemotherapy. In: Functional Preservation and Quality of Life in Head and Neck Radiotherapy. Harari et al, eds. 2-3-214, 2009.
    8. Yoon HH and Gibson MK. Molecular Outcome Prediction in Esophageal Cancer. ed. Jobe, B, editor. Esophageal Tumors: Practice and Principles, 2009.
    9. Hristov B, Gibson MK and Bajaj G. Early Treatment with Radiation and Chemotherapy. Ed. Koch, WM. Early Diagnosis and Treatment of Cancer: Head and Neck Cancer, 2010.
    10. Sampliner, RE and Gibson MK. Epidemiology, Pathobiology and Clinical Manifestations of Esophageal Cancer. In: UpToDate, continuously updated.
    11. Atasoy, A, Gibson MK and Berry, MF. Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas. In: UpToDate, continuously updated.
    12. Komatsu Y and Gibson MK. Esophageal Cancer: in Clinical Decision Support: Oncology, edited by Bacon BR, Forsmark C, Spechler SJ. Decision Support in Medicine, LLC. Wilmington, DE, 2013.
    13. Komatsu Y and Gibson MK. Current Therapy for Esophageal Adenocarcinoma. Esophageal Cancer – Cell and Molecular Biology, Biomarkers, Nutrition and Treatment, pp 153-170, 2012.
    14. Bhatt AJ, Dhaliwal AS, Gibson MK. Targeted Therapy for Esophageal Adenocarcinoma. Oncology and Hematology Review. In Press
    15. Wang D, Gibson MK and Komatsu Y. Esophageal Tumors: in Clinical Decision Support: Gastroenterology and Hepatology, edited by Bacon BR, Forsmark C, Spechler SJ. Decision Support in Medicine, LLC. Wilmington, DE, 2013.
Published Abstracts:
    1. M. K. Gibson, S. Abraham, T-T. Wu, B. Burtness, A. Forastiere . Epidermal growth factor receptor, p53 mutation and pathologic response predict survical in patient with locally advanced esophageal cancer treated with preoperative Chemoradiotherapy. 2003 ASCO Annual Meeting. Proc Am Soc Clin Oncol 22: 2003 (abstr 1030).
    2. B. Burtness, M. K. Gibson, J. Lacy, G. Mirto, L. Thomas, R. Sipples, V. Syombathy, J. Murren, A. A. Forastiere. Irinotecan and docetaxel combination for advanced esophageal cancer. 2004 Gastrointestinal Cancers Symposium Abstract No: 62.
    3. M. K. Gibson, M. Brock, E. Montgomery, J. Herman, S. Baylin, E. Heath, R. Heitmiller, A. A. Forastiere.  Pathologic downstaging with taxane based neoadjuvant chemotherapy correlates with increased survival in patients with locally
      advanced esophageal cancer. 2005 ASCO Annual Meeting. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4039.
    4. B. Burtness, M. K. Gibson, J. Lacy, E. Rowen, L. Thomas, R. E. Sipples, M. L. McGurk, J. Murren, A. Forastiere. Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients 2005 ASCO Annual Meeting. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4070.
    5. M. K. Gibson, Mezzadra, L. Kleinberg, S. Jagannath, M. Brock, N. Abdallah, M. Rudek, D. Berman, A. Forastiere, S. Altiok. Predicting and monitoring tumor response to epidermal growth factor receptor inhibitor gefitinib in patients with locally advanced esophageal adenocarcinoma. 2007 ASCO Annual Meeting. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14112.
    6. Tomoharu Miyashita, Todd Armstrong, Jiaai Wang, Furhawn Shah, Michael Gibson, Kiyoshi Yoshimura, Guy Marti, Mark Duncan, Elizabeth Montgomery, Elizabeth Jaffee, and John Harmon. Granulocyte macrophage colony stimulating factor (GM-CSF) transfected whole cell vaccine impedes carcinogenesis in a rat reflux model. 98th AACR Annual
      Meeting-- Apr 14-18, 2007; Los Angeles, CA. Abstract #4903
    7. H. Yoon, K. M. Murphy, M. K. Gibson. Clinical outcome prediction in esophageal adenocarcinoma based on tumor and germ-line single nucleotide polymorphisms (SNP) in DNA-repair pathways. Journal of Clinical Oncology, 2007 ASCO Annual Meeting. Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 15144.
    8. M. K. Gibson A. H. Zaidi, J. M. Davison, B. Hough, A. F. Sanz, T. Foxwell, T. Hoppo, Y. Komatsu, K. S. Nason, C. Rotoloni, U. Malhotra, A. Atasoy, C. Smith, J. D. Luketich, B. A. Jobe . Phase I trial of pemetrexed, cetuximab, and concurrent radiotherapy (RT) in head and neck cancer (HNC). Abstract 2008 ASCO Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 2540).
    9. M. S. Kies, M. K. Gibson, S. W. Kim, P. Savvides, G. R. Blumenschein, F. Worden, H. Chen, J. R. Grandis, A. E. Argiris. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis. 2008 ASCO Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6072).
    10. J. R. Grandis, S. Y. Lai, F. R. Esteve, S. W. Kim, R. L. Ferris, M. K. Gibson, R. Johnson, D. E. Heron, J. T. Johnson, A. E. Argiris. Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac (S): a feasibility report. 2008 ASCO Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6037).
    11. V. A. Passero, B. F. Branstetter, D. E. Heron, M. K. Gibson, S. Y. Lai, S. W. Kim, R. L. Ferris, J. R. Grandis, J. T. Johnson, A. E. Argiris. How to best assess tumor response after curative chemoradiotherapy (CRT) for head and neck squamous cell carcinomas (HNSCC): RECIST or PET/CT? 2008 ASCO Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6023).
    12. B. T. McLaughlin, J. Diacopoulos, R. Carrau, D. E. Heron, R. P. Smith, M. K. Gibson, R. L. Ferris, J. R. Grandis, J. T. Johnson, A. E. Argiris. Utilization of gastrostomy tubes during chemoradiotherapy for head and neck cancer: The University of Pittsburgh experience. 2008 ASCO Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 20657).
    13. T. M. Feinstein, L. E. Raez, K. K. Rajasenan, M. K. Gibson, P. Savvides, M. V. Karamouzis,
      N. Garg, R. Johnson, B. F. Branstetter, A. E. Argiris. Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial. 2008 ASCO Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6069).
    14. A. E. Argiris, M. K. Gibson, D. E. Heron, R. P. Smith, R. L. Ferris, S. Y. Lai, S. W. Kim, B. F. Branstetter, J. T. Johnson, J. R. Grandis. Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). 2008 ASCO Annual Meeting. J Clin Oncol 26: 2008
      (May 20 suppl; abstr 6002).
    15. Harry Yoon, Mark Powell, Michael Gibson, Elizabeth Montgomery, Michael
      Hafez, Paul Catalano, Geoffrey Liu, Todd Skaar, M Dolan, Xifeng Wu, Robert Diasio, Arlene Forastiere, Al Benson, Lawrence Kleinberg, and Kathleen Murphy. Abstract #1621: Outcome prediction based on genetic polymorphisms (GPs) in epidermal growth factor (EGF) pathway in patients (pts) with esophageal adenocarcinoma
      (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1621.
    16. M. Romkes, T. M. Feinstein, S. Zhong, S. Buch, M. K. Gibson, K. Skovira, A. Argiris. TS
      and MTHFR gene polymorphisms in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head or neck (SCCHN) treated with pemetrexed (P) and bevacizumab (B). 2009 ASCO Annual Meeting. J Clin Oncol 27, 2009 (suppl; abstr e17011).
    17. B. Hough, M. Posner, C. Chung, J. Hainsworth, J. Horan, J. Chick, M. K. Gibson. A phase II study of single agent OSI-7904L in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). 2009 ASCO Annual Meeting. J Clin Oncol 27, 2009 (suppl; abstr e17005).
    18. H. H. Yoon, M. Powell, K. Murphy, E. A. Montgomery, M. J. Hafez, G. Liu, A. A. Forastiere, A. B. Benson, L. R. Kleinberg, M. K. Gibson. Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). 2009 ASCO Annual Meeting. J Clin Oncol 27:15s, 2009 (suppl; abstr 4530).
    19. Pennathur A, Landreneau RJ, Ward J, Land S, Luong TM, Gibson M, Schuchert M, Luketich JD. Lymph Node Status Predicts Recurrence After Esophagectomy Following Neoadjuvant Therapy. Presented (Oral Presentation) at 56th Southern Thoracic Surgical Association Annual Meeting, Marco Island, FL November 2009.
    20. DeFoe SG, Pennathur A, Flickinger JC, Heron DE, Gibson MK, Luketich JD, Greenberger JS.Neo- adjuvant Chemotherapy Vs Neo-adjuvant Chemoradiation Therapy followed by Esophagectomy versus Definitive Chemoradiation Therapy in Management of Locally advanced Esophageal Carcinoma: A Single Institution Study. International Journal of Radiation Oncology*Biology*Physics;75 (3):S273 Suppl. S 2009.
    21. Katie S. Nason, James D. Luketich, Blair A. Jobe, Matthew J. Schuchert, Kevin McGrath,Michael Gibson, Jon M. Davison. Pathologic Features of the Primary Tumor Predict Recurrence and Survival After Esophagectomy for T1 Esophageal Adenocarcinoma. AGA Abstracts, Mo1881; S-668. Digestive Disease Week Annual Meeting, Poster Presentation, June 2011.
    22. M. K. Gibson, P. J. Catalano, L. Kleinberg, C. A. Staley, E. Montgomery, W. Song, M. F. Mulcahy, L. P. Leichman, A. B. Benson. E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5- fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. 2010 ASCO Annual Meeting. J Clin Oncol 28:15s, 2010 (suppl; abstr 4064).
    23. R. L. Ferris, D. E. Heron, S. Kim, M. K. Gibson, D. Posluszny, R. R. Seethala, W. E. Gooding, J. T. Johnson, J. R. Grandis, A. Argiris. Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): Mature results with HPV analysis. 2010 ASCO Annual Meeting. J Clin Oncol 28:15s, 2010 (suppl; abstr 5515).
    24. A. Atasoy, H. Yoon, A. M. Egloff, R. L. Ferris, A. H. Zaidi, B. Hough, A. A. Forastiere, B. A. Jobe, K. S. Nason, M. K. Gibson. Phase II study of irinotecan plus panitumumab as second- line therapy for patients with advanced esophageal adenocarcinoma (EAC). 2010 ASCO Annual Meeting. J Clin Oncol 28:15s, 2010 (suppl; abstr TPS206).
    25. R. A. Juergens, M. K. Gibson, S. C. Yang, M. Brock, R. Heitmiller, N. Tsottles, M. A. Rudek, M. Canto, L. Kleinberg, A. A. Forastiere. Phase II study of neoadjuvant and adjuvant gefitinib
      (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC). 2010 ASCO Annual Meeting. J Clin Oncol 28, 2010 (suppl; abstr e14532).
    26. C. Van Waes, A. G. Duffy, N. L. Simone, M. K. Gibson, Y. Arai, S. F. Rudy, T. Cooley- Zgela, M. Nyati, J. J. Wright, A. Argiris. Early disease progression in a phase I study of bortezomib (B), cetuximab (C), and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma of the head and neck (SCCHN). 2010 ASCO Annual Meeting. J Clin Oncol 28:15s, 2010 (suppl; abstr 2575).
    27. A. P. Kotsakis, D. E. Heron, G. J. Kubicek, R. L. Ferris, S. Kim, M. K. Gibson, U. Duvvuri, J. R. Grandis, J. T. Johnson, A. Argiris. Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). 2010 ASCO Annual Meeting.
      J Clin Oncol 28:15s, 2010 (suppl; abstr TPS264).
    28. K. S. Nason, B. A. Jobe, T. L. Vaughan, M. K. Gibson, M. J. Schuchert, G. E. Switzer, J. L. Weissfeld, J. D. Luketich. Association of endoscopic screening and surveillance for Barrett's esophagus with survival from esophageal adenocarcinoma. 2010 Gastrointestinal Cancers Symposium. Abstract No:11.
    29. M. K. Gibson, A. H. Zaidi, J. M. Davison, B. Hough, A. F. Sanz, T. Foxwell, T. Hoppo, Y. Komatsu, K. S. Nason, C. Rotoloni, U. Malhotra, A. Atasoy, C. Smith, J. D. Luketich, B. A. Jobe. Prevention of Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC) in the levrat rat model of EAC by treatment with a smoothened (SMO) inhibitor. 2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr 4129).
    30. A. Argiris, A. P. Kotsakis, S. Kim, F. P. Worden, P. Savvides, M. K. Gibson, G. R. Blumenschein, H. X. Chen, J. R. Grandis, M. S. Kies. Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results. 2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr 5564).
    31. U. Malhotra, A. H. Zaidi, A. Atasoy, T. Hoppo, A. F. Sanz, Y. Komatsu, T. Foxwell, K. S. Nason, J. D. Luketich, J. M. Davison, D. P. Normolle, B. A. Jobe, M. K. Gibson. Differentialup-regulation of survivin/BIRC5 in esophageal adenocarcinoma compared with normal squamous epithelium. 2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr e14602).
    32. A. Argiris, A. P. Kotsakis, S. Kim, F. P. Worden, P. Savvides, M. K. Gibson, G. R. Blumenschein, H. X. Chen, J. R. Grandis, M. S. Kies. Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results. 2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr 5564).
    33. M. K. Gibson, A. H. Zaidi, J. M. Davison, B. Hough, A. F. Sanz, T. Foxwell, T. Hoppo, Y. Komatsu, K. S. Nason, C. Rotoloni, U. Malhotra, A. Atasoy, C. Smith, J. D. Luketich, B. A. Jobe. Prevention of Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC) in the levrat rat model of EAC by treatment with a smoothened (SMO) inhibitor. 2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr 4129).
    34. U. Malhotra, A. H. Zaidi, A. Atasoy, T. Hoppo, A. F. Sanz, Y. Komatsu, T. Foxwell, K. S. Nason, J. D. Luketich, J. M. Davison, D. P. Normolle, B. A. Jobe, M. K. Gibson. Differentialup-regulation of survivin/BIRC5 in esophageal adenocarcinoma compared with normal squamous epithelium. 2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr e14602).
    35. Davison JM, Luketitch JD, Gibson MK, Landreneau R, Nason KN. Identifying Low-Risk andHigh-Risk T1 Esophageal Adenocarcinoma Based on Pathologic Risk Factors. United States and Canadian Academy of Pathology Annual Meeting, Platform Presentation, March 2011.
    36. Michael K. Gibson, Ali H Zaidi, Xuemei Zeng, Jon M. Davison, Tyler Foxwell, Toshitaka Hoppo, Yoshihiro Komatsu, Katie Sue Nason, Christina Rotoloni, Astha Bhatt, Juliann Kosovec, Cornelia Smith, William L Bigbee, James D. Luketich, Blair A Jobe. Evaluation of proteomic profiles of normal mucosa, Barrett’s esophagus (BE), and esophageal adenocarcinoma (EAC) obtained from humans and the Levrat’s rat model of BE/EAC. 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr e14689).
    37. Joseph A Califano, Robert L. Ferris, Joel Brian Epstein, Marion Boyd Gillespie, Lawrence Eric Feldman, Michael K. Gibson, Kristen B. Pytynia, Zubair Khan. A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract. 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr 5528).
    38. Prakash Varadarajan, Athanasios Panayotis Kotsakis, Daniel Martin, Jorge Silvio Gutkind,Michael K. Gibson, Athanassios Argiris. Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr 5541).
    39. Jon M. Davison, Shane Ellis, Tyler Foxwell, Ali H Zaidi, Blair A Jobe, Michael K. Gibson,Shih-Fan Kuan, Katie Sue Nason. Improving risk stratification in superficial (T1) gastroesophageal adenocarcinoma: Association of the intestinal phenotype (MUC2 positive) with prognosis. 2012 Markers in Cancer. J Clin Oncol 30: 2012 (suppl 30; abstr 33).
    40. Gloria Terase Minella, James D. Luketich, Jon M. Davison, Dan Winger, Ryan M. Levy,Michael K. Gibson, Arjun Pennathur, Katie Sue Nason. Effect of the revised AJCC staging (7th edition) on prognostic stratification in patients with surgically resected esophageal squamous cell carcinoma. 2013 Gastrointestinal Cancers Symposium. J Clin Oncol 30: 2012 (suppl 34; abstr 15).
    41. Brian A. Boone, Jennifer Steve, Alyssa M. Krasinskas, Amer H. Zureikat, Barry C. Lembersky, Michael K. Gibson, Ronald Stoller, Herbert J. Zeh, Nathan Bahary. Outcomes with FOLFIRINOX for locally advanced pancreatic cancer. 2013 Gastrointestinal Cancers Symposium. J Clin Oncol 30: 2012 (suppl 34; abstr 256).
    42. Deirdre Jill Cohen, Paul J. Christos, Joseph A. Sparano, Hedy Lee Kindler, Daniel Virgil Thomas Catenacci, Tanios B. Bekaii-Saab, Sanaa Tahiri, Yelena Yuriy Janjigian, Michael K. Gibson, Emily Chan, Lakshmi Rajdev, Susan Urba, James Lloyd Wade, Peter Kozuch, Erica Love, Katherine Vandris, Naoko Takebe, Howard S. Hochster . A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study. 2013 Gastrointestinal Cancers Symposium. J Clin Oncol
      30: 2012 (suppl 34; abstr 67).
    43. Cohen, Deirdre , Chan, Emily, Hochster, Howard, Christos, Paul, Sparano Joseph, Kindler, H., Catenacci, Daniel, Bekaii-Saab, Tanios, Janjigian Yelena Y., Tahiri, Sanaa, Gibson, Michael K., Urba, Susan, Lakshmi, Rajdev, Wade, James L.,Kozuch, P., Love, Erica, Vandris, Katherine. Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. 2013 ASCO Annual Meeting. Abstract ID: 4011.
    44. Gloria Terase Minella, James D. Luketich, Jon M. Davison, Dan Winger, Ryan M. Levy,Michael K. Gibson, Arjun Pennathur, Katie Sue Nason. Effect of the revised AJCC staging (7th edition) on prognostic stratification in patients with surgically resected esophageal squamous cell carcinoma. 2013 ASCO Annual Meeting. Abstract ID: 4103.
    45. Athanassios Argiris, James Ohr, Greg J. Kubicek, Uma Duvvuri, Dwight Earl Heron, Athanasios Panayotis Kotsakis, Christina Spencer, Seungwon Kim, Jennifer R. Grandis, Jonas Talmadge Johnson, Julie E. Bauman, Michael K. Gibson, Robert L. Ferris. Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). 2013 ASCO Annual Meeting. Abstract ID: 6043.
    46. Zahoor H, Luketich JD, Weksler B, Winger DG, Christie NA, Levy RM, Gibson MK, Nason KS. Prognostic stratification in esophagogastric adenocarcinoma in the revised AJCC staging (7th edition). Journal of Clinical Oncology. 2014 Jan 10;32(3S). 2014 ASCO GI Symposium. Abstract no. 92.
    47. J. Vargo1, R. L. Ferris2, J. Ohr3, D. A. Clump1, K. Davis2, J. Johnson2, M. Gibson3, B. F. Branstetter4, D. E. Heron. Re-irradiation With Stereotactic Body Radiotherapy Plus
      Cetuximab in Patients With Recurrent Previously-irradiated Squamous Cell Carcinoma of the Head and Neck: A Prospective Phase II Trial. ASTRO 56th Annual Meeting, November 2014.
    48. Anuj Kishor Patel, Michael K. Gibson, James Ohr, David Friedland, James D. Luketich, Ryan M. Levy, Jon M. Davison, Aatur D. Singhi, Reetesh K. Pai, Weijing Sun. Trastuzumab administration in HER2-postive gastric or GEJ cancer: Analysis of clinical practice. 2014 ASCO Annual Meeting, eAbstract e17681.
    49. Panayiotis Savvides, Sabarish Ayyappan, Min Yao, Rod Rezaee, Chad Zender, Jay Wasman, Pingfu Fu, Mitchell Machtay, Pierre Lavertu, Michael K. Gibson. Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). 2014 ASCO Annual Meeting, Abstract 6070.
    50. Haris Zahoor, James D. Luketich, Benny Weksler, Dan G. Winger, Neil A. Christie, Ryan M. Levy, Michael K. Gibson, Katie Sue Nason. The revised AJCC staging (7th edition) and prognostic stratification in esophagogastric adenocarcinoma. 2014 ASCO Annual Meeting, Abstract 4038.

 

Michael K. Gibson

Associate Professor

 

  • : 216-286-6741
    Fax: 216-844-5759
  • DEPARTMENTMedical Director, Head and Neck Clinical Trials Unit
    Case Western Reserve University
  • COUNTRY USA